News

Brian Freed

Dr. Brian Freed leads RheumaGen’s R&D. He is Professor of Medicine and Immunology at the University of Colorado School of Medicine, Anschutz Medical Campus, and he is Founder and Executive Director of CU Anschutz’s ClinImmune, one of the largest nonprofit clinical laboratories in the U.S. ClinImmune has generated over $200M in clinical revenue. Dr. Freed is the lead inventor of RheumaGen’s breakthrough HLA gene-editing therapies. He is a world-class expert in the HLA gene, with over 40 years of experience and more than 100 publications in the areas of immunogenetics, biotherapeutics, histocompatibility, transplantation, and stem-cell banking.

For Dr. Freed’s full CV and complete list of publications, click here.

Selected Publications:

• Roark CL, Anderson KM, Simon LJ, Schuyler RP, Aubrey MT, Freed BM.  Multiple HLA epitopes contribute to Type I diabetes susceptibility.  Diabetes 63:323, 2014.
• ­Anderson KM, Roark CL, Portas M, Aubrey MT, Rosloniec EF, Freed BM.  A molecular analysis of the shared epitope hypothesis. Binding of arthritogenic peptides to DRβ1*04 alleles.  Arthritis Rheum 68:1627, 2016.
• Anderson KM, Stastny T, Freed BM.  Binding of carbamylated collagen258-272 to HLA-DR alleles associated with susceptibility and resistance to RA.  Arthritis Rheum 68:2051, 2016.
• Roark CL, Anderson KM, Aubrey MT, Rosloniec EF, Freed BM.  Arthritogenic peptide binding to DRβ1*01 alleles correlates with susceptibility to rheumatoid arthritis.  J Autoimmunity 72:25, 2016.

Clinical Trial Experience:

• IND #11084 for human islet transplantation at the University of Colorado (2003-2004).
• IND 10-CBA (sponsored by National Marrow Donor Program) for umbilical cord blood transplantation (2005-present).
• BLA #1855 for HPC Cord Blood at ClinImmune Labs (May 2012-present).
• BLA #1873 for AlloCord (HPC Cord Blood) for St. Louis Cord Blood Bank (2018-present).
• IDE CD34 Isolation from Haploidentical Donors for Cord Blood Transplantation (2018-2022). 
• IND #18416 Phase I Open Label Safety Study of Umbilical Cord Lining Mesenchymal Stem Cells (CorliCyte®) to Close Chronic Diabetic Wounds (2019-2022).

Patents:

• U.S. Provisional Patent Application Serial Number 62/655,198: A Method of Transporting Mesenchymal Stem Cells by Means of a Transporting Solution and a Method of Administering Stem Cells to Wounds, filed on April 9, 2018.
• U.S. Patent PCT/US2018/029302; Methods of Treating Rheumatoid Arthritis Using RNA-Guided Genome Editing of HLA Gene, International filing April 25, 2018.
• U.S. Patent PCT/US2022/028645; Pocket Engineering of HLA Alleles for Treating Autoimmunity, filed May 10, 2022.